Online citations, reference lists, and bibliographies.
← Back to Search

Synergistic Effect Of CTLA-4 Blockade And Cancer Chemotherapy In The Induction Of Anti-Tumor Immunity

W. Lesterhuis, Joanne Salmons, A. Nowak, Esdy N. Rozali, Andrea Khong, I. Dick, Julie A. Harken, B. Robinson, R. Lake
Published 2013 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Several chemotherapeutics exert immunomodulatory effects. One of these is the nucleoside analogue gemcitabine, which is widely used in patients with lung cancer, ovarian cancer, breast cancer, mesothelioma and several other types of cancer, but with limited efficacy. We hypothesized that the immunopotentiating effects of this drug are partly restrained by the inhibitory T cell molecule CTLA-4 and thus could be augmented by combining it with a blocking antibody against CTLA-4, which on its own has recently shown beneficial clinical effects in the treatment of patients with metastatic melanoma. Here we show, using two non-immunogenic murine tumor models, that treatment with gemcitabine chemotherapy in combination with CTLA-4 blockade results in the induction of a potent anti-tumor immune response. Depletion experiments demonstrated that both CD4(+) and CD8(+) T cells are required for optimal therapeutic effect. Mice treated with the combination exhibited tumor regression and long-term protective immunity. In addition, we show that the efficacy of the combination is moderated by the timing of administration of the two agents. Our results show that immune checkpoint blockade and cytotoxic chemotherapy can have a synergistic effect in the treatment of cancer. These results provide a basis to pursue combination therapies with anti-CTLA-4 and immunopotentiating chemotherapy and have important implications for future studies in cancer patients. Since both drugs are approved for use in patients our data can be immediately translated into clinical trials.
This paper references
10.1016/J.YONC.2012.07.009
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
A. Tsao (2012)
10.1007/s10637-009-9376-8
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
E. Hersh (2009)
10.1002/ijc.25756
Gemcitabine depletes regulatory T‐cells in human and mice and enhances triggering of vaccine‐specific cytotoxic T‐cells
Lorna Rettig (2011)
10.1038/nrc1613
Immunotherapy and chemotherapy — a practical partnership
R. Lake (2005)
10.1038/nrd3500
Cancer immunotherapy – revisited
W. Lesterhuis (2011)
Anti-CTLA-4 and Cancer Chemotherapy PLOS ONE | www.plosone
10.1038/onc.2010.500
Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress
I. Martins (2011)
10.4049/jimmunol.170.10.4905
Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells1
A. Nowak (2003)
Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors.
A. Nowak (2003)
10.1007/s00262-008-0653-8
Ipilimumab: controversies in its development, utility and autoimmune adverse events
J. Weber (2008)
10.1038/sj.bjc.6605465
Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses
W. Liu (2010)
10.1016/J.VACCINE.2003.10.048
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems.
P. Gregor (2004)
10.1038/nm1523
Calreticulin exposure dictates the immunogenicity of cancer cell death
M. Obeid (2007)
10.1158/0008-5472.CAN-11-1138
The ICOS/ICOSL pathway is required for optimal antitumor responses mediated by anti-CTLA-4 therapy.
T. Fu (2011)
10.1172/JCI40269
Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.
R. Ramakrishnan (2010)
Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice.
M. B. Mokyr (1998)
10.1172/JCI43656
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice.
W. Lesterhuis (2011)
10.1007/s00262-007-0291-6
The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses
M. Chakraborty (2007)
Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy.
A. Nowak (2002)
10.1158/1535-7163.MCT-11-1014
CTLA-4 Blockade Expands Infiltrating T Cells and Inhibits Cancer Cell Repopulation during the Intervals of Chemotherapy in Murine Mesothelioma
Licun Wu (2012)
10.1073/pnas.0806075105
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
C. Liakou (2008)
10.1056/NEJMoa1104621
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.
C. Robert (2011)
Restoration of the immunogenicity of cisplatininduced cancer cell death by endoplasmic reticulum stress
I Martins (2011)
10.1158/0008-5472.CAN-10-2670
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice.
Bethany L. Mundy-Bosse (2011)
10.1073/pnas.1016791108
Single dose of anti–CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
Virginia Pedicord (2010)
10.1056/NEJMoa1003466
Improved survival with ipilimumab in patients with metastatic melanoma.
F. S. Hodi (2010)
10.1056/NEJMoa1200690
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
S. Topalian (2012)



This paper is referenced by
10.2741/4487
Tumor abolition and antitumor immunostimulation by physico-chemical tumor ablation.
Y. Keisari (2017)
10.18632/ONCOTARGET.3487
Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model
Licun Wu (2015)
10.1016/j.drudis.2017.05.016
Understanding the checkpoint blockade in lung cancer immunotherapy.
M. D. Dal Bello (2017)
10.1002/eji.201444722
Tumor‐infiltrating dendritic cells exhibit defective cross‐presentation of tumor antigens, but is reversed by chemotherapy
A. McDonnell (2015)
10.1186/s12967-014-0245-7
Neoadjuvant anti-tumor vaccination prior to surgery enhances survival
Scott A Fisher (2014)
10.3389/fimmu.2015.00516
Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy
K. Kersten (2015)
10.1177/1533033819869949
The Prognostic Landscape of Tumor-Infiltrating Immune Cells and Immune Checkpoints in Glioblastoma
Shiman Wu (2019)
10.1093/annonc/mdy551
Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors
K. Heinhuis (2019)
10.1136/jitc-2019-000367
Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study
K. Feng (2020)
10.1586/14737140.2015.1086270
Breast cancer and immunology: biomarker and therapeutic developments
C. Santa-Maria (2015)
10.3389/fonc.2014.00026
Recent Technological Advances in Using Mouse Models to Study Ovarian Cancer
C. House (2014)
Implication des cellules myéloïdes immunosuppressives (MDSC) et des lymphocytes TH17 dans l’efficacité des chimiothérapies et de l’immunothérapie
E. Limagne (2017)
10.1165/rcmb.2013-0472TR
Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
R. Wong (2014)
10.1093/neuonc/nou212
Immunotherapy advances for glioblastoma.
D. Reardon (2014)
10.1016/B978-012372551-6/50077-8
Immune Stimulatory Features of Classical Chemotherapy
W. Joost Lesterhuis (2013)
10.1016/B978-1-4557-3383-5.00082-8
82 – Pleural Tumors
V. Broaddus (2016)
10.1016/j.coi.2015.12.003
Chemotherapy and immunotherapy: mapping the road ahead.
A. Cook (2016)
Enhancing immunity against melanoma using Type I interferon
Rachael M. Zemek (2013)
10.1016/S1470-2045(14)70267-0
Chemoimmunotherapy: still waiting for the magic to happen.
A. Nowak (2014)
10.1080/2162402X.2016.1261241
Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma
E. Marcq (2017)
10.1186/1471-2407-14-969
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40
Andrea Khong (2014)
10.2217/LMT.15.23
Novel insights into the pathophysiology and treatment of malignant pleural mesothelioma
Alistair M. Cook (2015)
10.1126/scitranslmed.aav7816
Sensitization to immune checkpoint blockade through activation of a STAT1/NK axis in the tumor microenvironment
Rachael M. Zemek (2019)
10.3390/cells9071727
Modulation of Determinant Factors to Improve Therapeutic Combinations with Immune Checkpoint Inhibitors
Magalie Dosset (2020)
10.3109/1354750X.2016.1160429
Immune response profiling of malignant pleural mesothelioma for diagnostic and prognostic biomarkers
J. Creaney (2016)
Centre for Microscopy, Characterisation and Analysis
Sorting Pre-Sort (2013)
10.1016/j.gendis.2018.05.003
Immunogenic effects of chemotherapy-induced tumor cell death
Y. Wang (2018)
Association of Cytotoxic T-lymphocyte Antigen-4 Polymorphisms with Malignant Bone Tumor Risk: A Meta-analysis.
C. Zhang (2016)
10.2217/LMT.14.27
Mouse models of mesothelioma: strengths, limitations and clinical translation
C. Robinson (2014)
10.12659/AJCR.909584
Nivolumab Immunotherapy in Malignant Mesothelioma: A Case Report Highlighting a New Opportunity for Exceptional Outcomes
R. G. Jones (2018)
10.1038/nrd.2016.233
Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity
W. Lesterhuis (2017)
10.1002/jcb.28678
Identification of Nrf2/STAT3 axis in induction of apoptosis through sub‐G 1 cell cycle arrest mechanism in HT‐29 colon cancer cells
Issa Tajmohammadi (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar